---
title: "Sionna Therapeutics: Hold Rating Maintained as Disappointing CF Data Drive Price Target Cut from $60 to $6"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295442258.md"
description: "Gaurav Maini of LifeSci Capital downgraded Sionna Therapeutics to Hold with a $6 price target, citing disappointing Phase 2a cystic fibrosis data that undermined confidence in the NBD1 stabilizer thesis. Stifel Nicolaus also downgraded the stock to Hold with a $7 target. The downgrade reflects uncertainty regarding clinical efficacy and mechanistic rationale, prompting a wait-and-see approach despite remaining cash runway."
datetime: "2026-08-10T19:35:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295442258.md)
  - [en](https://longbridge.com/en/news/295442258.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295442258.md)
generator: "portal-rs"
---

# Sionna Therapeutics: Hold Rating Maintained as Disappointing CF Data Drive Price Target Cut from $60 to $6

In a report released today, Gaurav Maini from LifeSci Capital downgraded Sionna Therapeutics, Inc. to a Hold, with a price target of $6.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Gaurav Maini has given his Hold rating due to a combination of factors tied mainly to the disappointing Phase 2a cystic fibrosis data and the resulting uncertainty around SION’s core NBD1 stabilizer thesis. The key sweat chloride endpoint showed essentially no clinically meaningful improvement despite drug exposure levels matching prior pharmacokinetic expectations, which he sees as undermining confidence in both the assay and the mechanistic rationale.

At the same time, he acknowledges that management is still analyzing the dataset, that baseline patient characteristics such as starting sweat chloride appear reasonable, and that questions around potential interactions with Trikafta need further clarification. Balancing these scientific and execution risks against Sionna’s remaining cash runway and the optionality from deeper data analyses, he reduces the price target to $6 but maintains a neutral stance, reflecting a wait-and-see approach rather than a fully bearish view.

Maini covers the Healthcare sector, focusing on stocks such as Tenax Therapeutics, Liquidia Technologies, and Tectonic Therapeutic. According to TipRanks, Maini has an average return of 24.2% and a 76.19% success rate on recommended stocks. 

In another report released today, Stifel Nicolaus also downgraded the stock to a Hold with a $7.00 price target.

### Related Stocks

- [SION.US](https://longbridge.com/en/quote/SION.US.md)
- [TENX.US](https://longbridge.com/en/quote/TENX.US.md)
- [LQDA.US](https://longbridge.com/en/quote/LQDA.US.md)
- [TECX.US](https://longbridge.com/en/quote/TECX.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [22:22 ETRobbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics](https://longbridge.com/en/news/296425061.md)
- [SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law](https://longbridge.com/en/news/296031680.md)
- [Robbins LLP is Investigating the Recent Stock Drop of Sionna Therapeutics; Contact the Firm for Information](https://longbridge.com/en/news/296143993.md)
- [12:50 ETSION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics](https://longbridge.com/en/news/295826918.md)
- [LifeSci Capital Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)](https://longbridge.com/en/news/296003421.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**